Trials / Completed
CompletedNCT00879008
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 345 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.
Detailed description
The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxifloxacin (Avelox, BAY12-8039) | Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-04-09
- Last updated
- 2014-06-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00879008. Inclusion in this directory is not an endorsement.